Physician profile
Haley Mudrick
NPI 1154976355
$21,469.73
in general payments reported to CMS, 2019-2025
22 companies · $6,467 in 2025
The $6,467 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,841 · 2022: $1,030 · 2023: $7,829 · 2024: $4,304 · 2025: $6,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,500.00 |
| Food and Beverage | $2,099.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17,676.54 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $707.62 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $506.99 | 2021-2024 | Xarelto |
| Pfizer INC. | $456.98 | 2021-2025 | |
| Amgen INC. | $347.72 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $315.85 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $303.60 | 2021-2023 | |
| Novo Nordisk INC | $155.81 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $154.64 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $138.39 | 2022-2023 | Verquvo |
| Impulse Dynamics (USA) INC. | $127.90 | 2022-2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $110.04 | 2021-2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $108.79 | 2021-2023 | |
| Amarin Pharma, INC. | $105.15 | 2021-2022 | |
| Edwards Lifesciences Corporation | $77.73 | 2021-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $43.59 | 2023 | Impella |
| Alnylam Pharmaceuticals INC. | $33.88 | 2021 | |
| Atricure, INC. | $30.80 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Esperion Therapeutics, INC. | $22.47 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $18.99 | 2024 | Arcalyst |
| Preventice Services, LLC | $17.11 | 2021 | |
| Cvrx, INC. | $9.14 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Mudrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.